Search

1st European EHA Sickle Cell Conference

EHA is teaming up with the Annual Scientific Conference on Sickle Cell and Thalassaemia, 2020 and the British Society of Haematology (BSH) to co-organize this first European Sickle Cell Conference; and also as a result of COVID-19 offer it as…

Read more

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

Read more

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more

Michel Boiron 1925-2018

It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).

Read more

New data exchange platform on rare diseases

The European Commission (EC) launched a new online knowledge-sharing platform – the European Platform on Rare Disease Registration (EU RD Platform) – on February 28, 2019.

Read more

European Research Initiative on CLL (ERIC)

ERIC is devoted to improving the outcome of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. The objectives of ERIC are to promote:

Research in all aspects of chronic lymphocytic leukemia and related diseases.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Read more

Abstract submission

Abstract procedureThe official abstract submission closed on March 1, 2025 (23:59 CET).

Read more